Education
About Us
Working with TipRanks
Follow Us
Moonlake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$16.25
-$0.83(-1.65%)
At close: 4:00 PM EST
$16.25
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)2.66M
Market Cap
$1.16B
Enterprise Value$873.43M
Total Cash (Recent Filing)$380.48M
Total Debt (Recent Filing)$75.73M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 26, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding70,847,404
10 Day Avg. Volume1,474,177
30 Day Avg. Volume2,663,867
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.62
Price to Sales (P/S)0.00
P/FCF Ratio-29.07
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-587.37
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$26.44Price Target Upside62.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development And ReadoutsConsistent efficacy signals and a favorable safety profile across the Phase II LEDA study and other ongoing dermatology and rheumatology trials mean multiple upcoming readouts could materially raise the drug's perceived value if results are positive.
Financial RunwayA recently completed equity offering extended the company's operational runway into 2028, supporting continuation of late-stage development without immediate need for additional financing.
Regulatory ClarityFDA feedback from a Type B meeting indicated existing pivotal trial data for sonelokimab may be sufficient to support a biologics license application, reducing regulatory uncertainty and increasing the likelihood of approval.
Bears Say
Pivotal Trial FailureFailure of a late-stage pivotal trial to meet its primary endpoint significantly increases doubt about the drug's chance of regulatory approval for the targeted skin disease.
Placebo Response UncertaintyA higher-than-expected placebo response in a pivotal study prevented statistical significance under the original analysis method, raising questions about that trial's contribution to a marketing application.
Valuation And Dilution RiskAnalyst reductions in probability of success and lowered peak market penetration, together with equity dilution and higher projected operating expenses, have pressured the stock's valuation and potential upside.
MoonLake Immunotherapeutics News
MLTX FAQ
What was Moonlake Immunotherapeutics’s price range in the past 12 months?
Moonlake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is Moonlake Immunotherapeutics’s market cap?
Moonlake Immunotherapeutics’s market cap is $1.16B.
When is Moonlake Immunotherapeutics’s upcoming earnings report date?
Moonlake Immunotherapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 26 days.
How were Moonlake Immunotherapeutics’s earnings last quarter?
Moonlake Immunotherapeutics released its earnings results on Nov 05, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.879 by -$0.221.
Is Moonlake Immunotherapeutics overvalued?
According to Wall Street analysts Moonlake Immunotherapeutics’s price is currently Undervalued.
Does Moonlake Immunotherapeutics pay dividends?
Moonlake Immunotherapeutics does not currently pay dividends.
What is Moonlake Immunotherapeutics’s EPS estimate?
Moonlake Immunotherapeutics’s EPS estimate is -0.99.
How many shares outstanding does Moonlake Immunotherapeutics have?
Moonlake Immunotherapeutics has 70,847,404 shares outstanding.
What happened to Moonlake Immunotherapeutics’s price movement after its last earnings report?
Moonlake Immunotherapeutics reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.879. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of Moonlake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.44 (62.71% Upside)
$26.44 (62.71% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 249.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.80%
12-Months-Change
Fundamentals
Return on Equity
-54.17%
Trailing 12-Months
Asset Growth
-20.05%
Trailing 12-Months
Company Description
Moonlake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$26.44
▲(62.71% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
Ownership Overview
36.85% Insiders
5.63% Mutual Funds
0.11% Other Institutional Investors
56.79% Public Companies and Individual Investors